NextCure, Inc. (NASDAQ:NXTC) Receives $23.00 Consensus Target Price from Analysts

Shares of NextCure, Inc. (NASDAQ:NXTC – Get Free Report) have received an average recommendation of “Hold” from the four analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $16.50.

A number of equities research analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of NextCure in a research report on Monday, April 27th. Zacks Research upgraded shares of NextCure from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 11th.

Get NextCure alerts:

View Our Latest Research Report on NextCure

Hedge Funds Weigh In On NextCure

Several hedge funds have recently made changes to their positions in NXTC. Ikarian Capital LLC acquired a new position in NextCure in the 4th quarter valued at about $3,382,000. Squadron Capital Management LLC purchased a new position in NextCure during the 4th quarter worth $3,363,000. Exome Asset Management LLC purchased a new position in NextCure during the 4th quarter worth $2,341,000. AWM Investment Company Inc. acquired a new stake in shares of NextCure in the 4th quarter worth $1,665,000. Finally, Cable Car Capital LP boosted its holdings in shares of NextCure by 13.1% in the second quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after acquiring an additional 88,040 shares in the last quarter. Hedge funds and other institutional investors own 42.65% of the company’s stock.

NextCure Stock Up 21.9%

NASDAQ:NXTC opened at $1.95 on Friday. The stock’s fifty day moving average is $6.07 and its two-hundred day moving average is $9.99. NextCure has a 52 week low of $1.55 and a 52 week high of $15.74. The stock has a market capitalization of $7.04 million, a price-to-earnings ratio of -0.11 and a beta of 1.42.

NextCure (NASDAQ:NXTC – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, beating the consensus estimate of ($2.10) by $0.23. On average, sell-side analysts expect that NextCure will post -7.9 EPS for the current fiscal year.

NextCure Company Profile

(Get Free Report)

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.

Featured Articles

• Five stocks we like better than NextCure
• AirJoule Unveils Prime System, Clearing Path to Commercialization
• Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
• Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
• Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.